Influenza Vaccine With Topical Imiquimod in Influenza Vaccine Non-responsive Children
Status:
Not yet recruiting
Trial end date:
2023-10-30
Target enrollment:
Participant gender:
Summary
Aims and hypotheses to be tested:
Primary objective
- To compare the IIV responses, in terms of seroconversion rates, using ID IIV with topical
5% imiquimod (IIV-Q-ID), ID influenza vaccine alone (IIV-ID), and the second dose of IM
influenza vaccine (IIV-IM) among children who are IIV non-responders.
Secondary objectives
- To determine the IIV non-responder rate in healthy Hong Kong children.
- To investigate the association between HLA molecules and IIV non-responsiveness.
Hypotheses
- We hypothesize that among IIV non-responder children, the seroconversion rate after ID
IIV with topical imiquimod will be significantly higher than a second IM IIV dose.
- We hypothesize that the IIV non-responder rate is approximately 5-10% in the paediatric
population.
- We hypothesize that certain HLA alleles are associated with IIV non-responders.